Roche's CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-stain biomarkers aid in ...
Next-generation biomarker cytology test supports World Health Organization's goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment ...
TUCSON, Ariz., June 16, 2015 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the publication of further results from the Primary ASC-US LSIL ...
The Food and Drug Administration approved the expanded use of the biomarker test CINtec PLUS Cytology that looks at HPV related biomarkers that could lead to cervical cancer. This is the first triage ...
Clearance of Type-Specific, Low-Risk, and High-Risk Cervical Human Papillomavirus Infections in HIV-Negative and HIV-Positive Women This was a cross-sectional comparative study of 200 consenting ...
Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the publication of further results from the Primary ASC-US LSIL Marker Study (PALMS) in this month's issue of ...
Women with borderline/mildly dyskaryotic (BMD) cytology smears are currently followed up with repeat testing at 6 and 18 months. The objective of this study is to analyse the cross-sectional and ...
To document the effect of bivalent HPV immunisation on cervical cytology as a screening test and assess the implications of any change, using a retrospective analysis of routinely collected data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results